Ro vs Hims: Branded GLP-1 Telehealth Compared
Ro and Hims are the two big public-facing telehealth platforms for branded GLP-1 weight loss. Both run an insurance pathway that can drive Wegovy to $0-$25/month for eligible users. The differences live in trust posture (Hims has a recent FDA warning letter, Ro doesn't), Trustpilot reputation (Ro is materially better at 3.7 vs 3.0), and product mix (Hims is branded-only post-settlement, Ro still offers compounded options).
Ro
3.6Established multi-vertical telehealth with insurance concierge for branded GLP-1
Hims & Hers
3.4Public-company telehealth, post-settlement branded-only GLP-1 supply
Reviewed by Designing Longevity Editorial·Last verified May 1, 2026
Bottom line
If you have commercial insurance covering Wegovy or Zepbound, both work, but Ro is the safer pick today: cleaner regulatory record, materially better Trustpilot score, longer BBB tenure, and a more mature insurance concierge. Choose Hims if you specifically want the new oral Wegovy pill or if you value public-company SEC disclosure as a transparency signal. Cash-pay users on compounded GLP-1 should look at TrimRx or Eden, not either of these.
Side-by-side at a glance
Who wins for each use case
We pick a winner per criterion and explain the reasoning. Skip to whichever rows match how you'd actually use the platform.
Insurance pathway for branded Wegovy
Winner: RoBoth have insurance concierges and both can land Wegovy at $0-$25/month with eligible coverage. Ro's concierge is more mature (longer-tenured BBB accreditation, larger ConsumerAffairs sample, fewer recent complaints). Hims's pathway is newer because it only became an authorized Novo seller in March 2026.
New oral Wegovy pill access
Winner: Hims & HersHims is one of the first telehealth channels to offer the FDA-approved oral Wegovy pill (early 2026), explicitly priced at $149/month medication plus membership. Ro carries injectable Wegovy and Ozempic but the oral pill is not yet a confirmed Ro offering at capture date.
Regulatory and legal track record
Winner: RoHims received twin FDA warning letters on September 9, 2025 for false or misleading marketing of compounded semaglutide and went through a public dispute with Novo Nordisk before the March 2026 settlement. Ro has no FDA enforcement action on the GLP-1 line. Ro is flagged for the industry-wide April 2025 FDA compounded topical finasteride alert (different product line), which is a softer counterweight than direct warning letters.
Customer service and complaint posture
Winner: RoTrustpilot is 3.7/5 across roughly 3,200 reviews for Ro vs 3.0/5 across roughly 8,000 for Hims, with Hims showing 28% one-star ratings (a bimodal distribution that signals a large slice of unhappy users). BBB is closer (Ro B since 2018, Hims A+ since 2018), but the wider review set favors Ro.
Public-company financial disclosure
Winner: Hims & HersHims is publicly traded as NYSE: HIMS, with quarterly 10-Qs and audited financials in the public record. Ro is private. For users who weight financial-transparency as a trust signal, Hims wins outright on this criterion alone.
Compounded GLP-1 still available
Winner: RoPer the March 2026 Novo settlement, Hims agreed to stop advertising compounded GLP-1; new patients there get branded only. Ro still offers both branded and compounded options through partner pharmacies. If compounded is what you want and you also want a multi-vertical platform, Ro is the only one of the two that still offers it.
Multi-vertical platform breadth
Winner: RoRo covers weight loss, men's health, hair loss, fertility, and skincare under one membership model with the longest tenure (founded 2017 as Roman). Hims covers similar ground but with a more recent track record on its compounded lines. If you want one provider for several needs, Ro's operational maturity edges it out.
Rubric scores side-by-side
Same six dimensions we use on every provider profile, weighted to a single 0-5 score. Click through to either profile for the verification details behind each row.
Licensure 20% weight
Accreditation 20% weight
Transparency 20% weight
Product quality 15% weight
Pricing 15% weight
Customer service 10% weight
Pricing in plain terms
Both run a membership-plus-medication model with insurance concierge for branded GLP-1. Ro: $45 first month, $145/month standard ($74/month annual prepay) plus medication. Hims: $39 first month, $149/month standard plus $149/month for oral Wegovy or higher for injectable. With eligible commercial insurance and a Novo Nordisk savings card, both can land Wegovy at $0-$25/month effective. For cash-pay users without insurance, neither matches the all-inclusive math of compounded specialists like TrimRx or Eden.
Read the full profiles
This comparison summarizes the head-to-head call. The full provider profiles include verification items, regulatory history, public-review aggregation, and the signup walkthrough.